Valuation : Myriad Genetics, Inc.

Market Cap 30Cr 26Cr 24Cr 22Cr 42Cr 2.91TCr 42Cr 289.46Cr 113.15Cr 1.46TCr 114.2Cr 111.73Cr 4.85TCr P/E 2026 *
-2x
P/E 2027 * -2.6x
Enterprise Value 30Cr 26Cr 24Cr 22Cr 42Cr 2.91TCr 42Cr 289.46Cr 113.15Cr 1.46TCr 114.2Cr 111.73Cr 4.85TCr EV / Sales 2026 *
0.39x
EV / Sales 2027 * 0.37x
Free-Float
96.03%
Yield 2026 *
-
Yield 2027 * -
1 day+1.92%
1 week-1.24%
Current month+11.19%
1 month-41.65%
3 months-19.08%
6 months-31.02%
Current year-48.29%
1 week 3
Extreme 3
3.27
1 month 2.74
Extreme 2.74
5.43
Current year 2.74
Extreme 2.74
7.15
1 year 2.74
Extreme 2.74
8.59
3 years 2.74
Extreme 2.74
29.3
5 years 2.74
Extreme 2.74
36.95
10 years 2.74
Extreme 2.74
50.44
Manager TitleAgeSince
Chief Executive Officer 54 30/04/2025
Director of Finance/CFO 43 16/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2026
Director TitleAgeSince
Chairman 67 23/03/2020
Director/Board Member 71 10/06/2010
Director/Board Member 66 25/09/2019
Date Insider Type Main position Quantity % Market Cap.
16/08/26 Tax

Chief Financial Officer

-8,761 0.0093%
11/06/26 Free

Chief Executive Officer

3,542 0.0038%
22/03/26 Tax

Chief Operating Officer

2,055 0.0022%
Change 5-day change 1-year change 3-year change Capi.($)
+1.92%-1.24%-46.37%-82.03% 30Cr
-1.40%+0.38%+165.39%+340.11% 2.26TCr
-0.40%+0.94%-36.16%-21.80% 1.04TCr
+0.92%+1.53%+362.55%+35.41% 844.94Cr
-1.64%+7.32%-30.98% - 745.49Cr
-0.35%+0.23%+76.76%+51.38% 655.79Cr
-0.12%-3.82%-14.67%-10.78% 593.63Cr
+0.05%+2.56%-10.40%-18.66% 444.02Cr
-2.48%-11.72%+56.86%+98.49% 433.28Cr
+0.26%-0.55%-19.52%-24.57% 284.98Cr
Average -0.32%+0.20%+50.35%+40.84% 732.92Cr
Weighted average by Cap. -0.71%+0.69%+92.03%+125.87%

Financials

2026 *2027 *
Net sales 78Cr 67Cr 62Cr 57Cr 107.81Cr 7.43TCr 108.11Cr 740.05Cr 289.3Cr 3.74TCr 291.97Cr 285.67Cr 12TCr 82Cr 71Cr 66Cr 60Cr 113.92Cr 7.85TCr 114.25Cr 782.05Cr 305.71Cr 3.96TCr 308.54Cr 301.88Cr 13TCr
Net income -14Cr -12Cr -12Cr -11Cr -20Cr -1.37TCr -20Cr -136.4Cr -53Cr -689.92Cr -54Cr -53Cr -2.28TCr -10Cr -8.91Cr -8.34Cr -7.64Cr -14Cr -991.38Cr -14Cr -99Cr -39Cr -499.65Cr -39Cr -38Cr -1.65TCr
Net Debt - -
Logo Myriad Genetics, Inc.
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Employees
2,700
Date Price Change Volume
27/26/27 $3.180 +1.92% 12,78,031
26/26/26 $3.120 -2.19% 12,88,004
25/26/25 $3.190 +4.59% 17,57,379
24/26/24 $3.050 -4.69% 13,52,465
21/26/21 $3.200 -0.62% 12,79,035
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
3.180USD
Average target price
3.769USD
Spread / Average Target
+18.51%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MYGN Stock